Solid Biosciences Inc. (SLDB) shareholders
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Joseph Edelman Joint filing with Perceptive Advisors LLC (11.20%), Perceptive Life Sciences Master Fund, Ltd. (11.20%) | 12,046,579 | 11.20% | 13D (active) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (10.80%), Peter Kolchinsky (10.80%) and 1 more | 12,036,126 | 10.80% | 13D (active) amendment | Nov 4, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (12.90%), Perceptive Life Sciences Master Fund, Ltd. (12.80%) | 11,969,079 | 12.90% | 13D (active) amendment | Mar 9, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (8.70%), Invus Public Equities Advisors, LLC (8.70%) and 2 more | 10,066,682 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 9,313,756 | 9.90% | 13D (active) amendment | Mar 13, 2026 |
| BCLS II Investco, LP Joint filing with Bain Capital Life Sciences Opportunities IV, L.P. (5.40%) | 8,604,852 | 8.80% | 13D (active) amendment | Mar 6, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (7.00%) | 6,875,957 | 7.00% | 13G (passive) | Jun 30, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (8.68%), Phillip Gross (8.68%) | 6,729,484 | 8.68% | 13G (passive) | Mar 31, 2025 |
| BlackRock, Inc. | 6,419,730 | 6.50% | 13G (passive) | Jun 30, 2026 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (7.60%) | 5,825,000 | 7.60% | 13G (passive) | Feb 18, 2025 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (5.14%), Robert Atchinson (5.14%) | 4,000,000 | 5.14% | 13G (passive) amendment | Sep 30, 2025 |
| Stichting Administratiekantoor Westend Joint filing with Invus Public Equities, L.P. (7.30%), Invus Public Equities Advisors, LLC (7.30%) and 5 more | 2,717,538 | 7.30% | 13G (passive) | Jan 11, 2024 |
| Adage Capital Partners GP, L.L.C. Joint filing with Adage Capital Partners, L.P. (7.25%), Adage Capital Management, L.P. (7.25%) and 2 more | 2,712,478 | 7.25% | 13G (passive) | Jan 8, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SLDB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,036,126 | 11.23% | $120.24M | +2,696,148 | 1.04% |
| Perceptive Advisors LLC | 11,906,646 | 11.10% | $118.95M | – | 1.79% |
| Bain Capital Life Sciences Investors, LLC | 9,808,819 | 9.15% | $97.99M | – | 5.83% |
| Siren, L.L.C. | 7,690,405 | 7.17% | $76.83M | – | 1.55% |
| BlackRock, Inc. | 6,934,248 | 6.47% | $69.27M | +1,975,894 | 0.00% |
| FMR LLC | 6,875,957 | 6.41% | $68.69M | +3,269,553 | 0.00% |
| Armistice Capital, LLC | 4,278,000 | 3.99% | $42.74M | +1,078,000 | 0.52% |
| State Street Corp | 4,175,365 | 3.89% | $41.71M | +3,049,878 | 0.00% |
| Jupiter Topco LLC | 4,043,605 | 3.77% | $40.38M | New | 0.02% |
| Vanguard Capital Management LLC | 4,009,922 | 3.74% | $40.06M | +1,335,298 | 0.00% |
| Rtw Investments, LP | 3,892,926 | 3.63% | $38.89M | New | 0.33% |
| Deep Track Capital, LP | 3,565,062 | 3.32% | $35.61M | – | 0.52% |
| Franklin Resources Inc | 3,440,708 | 3.21% | $34.37M | +1,247,771 | 0.01% |
| Citadel Advisors LLC | 2,815,122 | 2.63% | $28.12M | +218,322 | 0.00% |
| Alyeska Investment Group, L.P. | 2,280,484 | 2.13% | $22.78M | +359 | 0.06% |
| Ameriprise Financial Inc | 2,225,783 | 2.08% | $22.24M | −213,066 | 0.00% |
| Vestal Point Capital, LP | 2,160,000 | 2.01% | $21.58M | −2,840,000 | 0.50% |
| Redmile Group, LLC | 1,948,695 | 1.82% | $19.47M | −63,200 | 1.31% |
| Geode Capital Management, LLC | 1,940,824 | 1.81% | $19.39M | +644,840 | 0.00% |
| Goldman Sachs Group Inc | 1,602,917 | 1.49% | $16.01M | +667,382 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 156 | 115M | 100.0% | 36 / 59 | 40 / 26 | 29M | 10M |
| Q1 2026 | 150 | 100M | 93.2% | 34 / 54 | 41 / 12 | 27M | 5M |
| Q4 2025 | 130 | 81M | 75.9% | 14 / 37 | 46 / 11 | 10M | 10M |
| Q3 2025 | 127 | 81M | 75.9% | 25 / 38 | 36 / 12 | 7M | 8M |
| Q2 2025 | 114 | 83M | 77.0% | 25 / 54 | 14 / 35 | 18M | 14M |
| Q1 2025 | 124 | 79M | 73.5% | 50 / 43 | 15 / 15 | 46M | 3M |
| Q4 2024 | 90 | 36M | 33.9% | 16 / 35 | 20 / 18 | 4M | 3M |
| Q3 2024 | 92 | 36M | 33.4% | 27 / 28 | 21 / 13 | 7M | 7M |
| Q2 2024 | 80 | 38M | 35.1% | 31 / 23 | 17 / 6 | 8M | 5M |
| Q1 2024 | 55 | 35M | 32.7% | 22 / 24 | 2 / 6 | 20M | 2M |
| Q4 2023 | 39 | 17M | 15.5% | 8 / 14 | 5 / 5 | 1M | 1M |
| Q3 2023 | 36 | 16M | 15.1% | 3 / 7 | 8 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
143 funds held SLDB in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SLDB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,148,576 | 2.94% | $31.45M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 2,606,779 | 2.43% | $19.13M | 0.36% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,582,269 | 2.41% | $25.80M | 0.24% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,052,984 | 1.91% | $20.51M | 0.02% | Jun 30, 2026 |
| Columbia Small Cap Growth Fund | 1,476,030 | 1.38% | $10.83M | 0.30% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 1,409,093 | 1.31% | $11.36M | 0.98% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 862,714 | 0.80% | $6.95M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 774,006 | 0.72% | $7.73M | 0.01% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 677,565 | 0.63% | $5.46M | 0.25% | Jul 31, 2026 |
| iShares Biotechnology ETF | 551,591 | 0.51% | $5.51M | 0.06% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 500,000 | 0.47% | $4.03M | 0.26% | Jul 31, 2026 |
| Columbia Small Cap Value Discovery Fund | 449,526 | 0.42% | $3.62M | 0.15% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 427,881 | 0.40% | $4.27M | 0.07% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 373,828 | 0.35% | $3.73M | 0.03% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 359,257 | 0.34% | $3.59M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alexander Cumbo | President and CEO, Director | 235,405 | 0.22% | Apr 21, 2026 |
| Gabriel Brooks | Chief Medical Officer | 97,241 | 0.09% | Oct 20, 2026 |
| Kevin Tan | CFO & Treasurer | 99,422 | 0.09% | Apr 21, 2026 |
| Jessie Hanrahan | Chief Regulatory Officer | 74,318 | 0.07% | Apr 21, 2026 |
| Paul Herzich | Chief Technology Officer | 72,638 | 0.07% | Apr 21, 2026 |
| David T. Howton | Chief Operating Officer | 105,077 | 0.10% | Apr 21, 2026 |
| Ilan Ganot | Director | 146,165 | 0.14% | Oct 26, 2026 |
| Ian F. Smith | Director | 141,585 | 0.13% | Oct 6, 2026 |
| Clare Kahn | Director | 2,960 | 0.00% | Jun 11, 2026 |
| Advisors Llc Perceptive | Director, 10% owner | 6,749,803 | 6.29% | Jun 11, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director, 10% owner | – | – | Jun 11, 2026 |
| Joseph Edelman | Director, 10% owner | 11,833,539 | 11.04% | Jun 11, 2026 |
| Adam Leo Stone | Director | 0 | – | Jun 11, 2026 |
| Sukumar Nagendran | Director | 34,258 | 0.03% | Jun 11, 2026 |
| Lynne Marie Sullivan | Director | – | – | Jun 11, 2026 |
| Martin I. Freed | Director | 53,763 | 0.05% | Jun 11, 2026 |
| Georgia Keresty | Director | – | – | Jun 11, 2026 |
| Perceptive Xontogeny Venture Fund, LP | Director, 10% owner | 6,833,539 | 6.37% | Feb 21, 2025 |
| Rajeev M. Shah | 10% owner | 8,709,882 | 8.12% | Jun 24, 2026 |
| Peter Kolchinsky | 10% owner | 109,661 | 0.10% | Jun 24, 2026 |
| Ra Capital Management, L.P. | 10% owner | 2,987,644 | 2.79% | Jun 24, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 787,586 | 0.73% | Jun 24, 2026 |
| BCLS II Equity Opportunities, LP | 10% owner | – | – | Feb 21, 2025 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | – | – | Feb 21, 2025 |
| Bain Capital Life Sciences Partners, LP | 10% owner | – | – | Feb 21, 2025 |
| BCIP Life Sciences Associates, LP | 10% owner | – | – | Feb 21, 2025 |
| Bain Capital Life Sciences Investors II, LLC | 10% owner | – | – | Feb 21, 2025 |
| BCLS II Investco, LP | 10% owner | – | – | Feb 21, 2025 |
| BCLS II Investco (GP), LLC | 10% owner | – | – | Feb 21, 2025 |
| Bain Capital Life Sciences Fund II, L.P. | 10% owner | 3,130,423 | 2.92% | Feb 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gabriel Brooks Chief Medical Officer | Oct 19, 2026 | Sale(10b5-1 plan) | −4,374 | $5.62 | $24.58K | 97,241 |
| Gabriel Brooks Chief Medical Officer | Oct 18, 2026 | Option exercise | +9,750 | – | – | 101,615 |
| Ian F. Smith Director | Oct 2, 2026 | Option exercise | +3,440 | – | – | 141,585 |
| Ian F. Smith Director | Jul 2, 2026 | Option exercise | +3,440 | – | – | 138,145 |
| Ian F. Smith Director | Apr 2, 2026 | Option exercise | +3,441 | – | – | 134,705 |
| Alexander Cumbo President and CEO, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −16,644 | $5.82 | $96.87K | 235,405 |
| Ilan Ganot Director | Feb 18, 2026 | Sale(10b5-1 plan) | −2,658 | $5.82 | $15.47K | 27,474 |
| Paul Herzich Chief Technology Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −3,616 | $5.82 | $21.05K | 72,638 |
| David T. Howton Chief Operating Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −7,469 | $5.82 | $43.47K | 105,077 |
| Jessie Hanrahan Chief Regulatory Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −4,134 | $5.82 | $24.06K | 74,318 |
| Gabriel Brooks Chief Medical Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −0 | $5.82 | $0 | 89,466 |
| Kevin Tan CFO & Treasurer | Feb 18, 2026 | Sale(10b5-1 plan) | −5,404 | $5.82 | $31.45K | 99,422 |
| Alexander Cumbo President and CEO, Director | Feb 13, 2026 | Option exercise | +30,031 | – | – | 252,049 |
| Ilan Ganot Director | Feb 13, 2026 | Option exercise | +4,861 | – | – | 30,132 |
| Paul Herzich Chief Technology Officer | Feb 13, 2026 | Option exercise | +7,187 | – | – | 76,254 |
| David T. Howton Chief Operating Officer | Feb 13, 2026 | Option exercise | +14,687 | – | – | 112,546 |
| Jessie Hanrahan Chief Regulatory Officer | Feb 13, 2026 | Option exercise | +8,125 | – | – | 78,452 |
| Gabriel Brooks Chief Medical Officer | Feb 13, 2026 | Option exercise | +10,937 | – | – | 95,029 |
| Kevin Tan CFO & Treasurer | Feb 13, 2026 | Option exercise | +10,625 | – | – | 104,826 |
| Ilan Ganot Director | Feb 4, 2026 | Sale(10b5-1 plan) | −7,205 | $6.44 | $46.40K | 25,271 |
| Gabriel Brooks Chief Medical Officer | Feb 4, 2026 | Sale(10b5-1 plan) | −12,616 | $6.44 | $81.25K | 84,092 |
| Alexander Cumbo President and CEO, Director | Feb 4, 2026 | Sale(10b5-1 plan) | −48,913 | $6.44 | $315.00K | 222,018 |
| Kevin Tan CFO & Treasurer | Feb 4, 2026 | Sale(10b5-1 plan) | −14,783 | $6.44 | $95.20K | 94,201 |
| Paul Herzich Chief Technology Officer | Feb 4, 2026 | Sale(10b5-1 plan) | −10,905 | $6.44 | $70.23K | 69,067 |
| David T. Howton Chief Operating Officer | Feb 4, 2026 | Sale(10b5-1 plan) | −18,894 | $6.44 | $121.68K | 97,859 |
| Jessie Hanrahan Chief Regulatory Officer | Feb 4, 2026 | Sale(10b5-1 plan) | −12,348 | $6.44 | $79.52K | 70,327 |
| David T. Howton Chief Operating Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −37,771 | $6.44 | $243.25K | 116,753 |
| Kevin Tan CFO & Treasurer | Feb 2, 2026 | Sale(10b5-1 plan) | −26,837 | $6.44 | $172.83K | 108,984 |
| Jessie Hanrahan Chief Regulatory Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −26,535 | $6.44 | $170.89K | 82,675 |
| Gabriel Brooks Chief Medical Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −28,335 | $6.44 | $182.48K | 96,708 |
| Alexander Cumbo President and CEO, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −80,258 | $6.44 | $516.86K | 270,931 |
| Paul Herzich Chief Technology Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −26,250 | $6.44 | $169.05K | 79,972 |
| Ilan Ganot Director | Jan 31, 2026 | Option exercise | +15,000 | – | – | 32,476 |
| David T. Howton Chief Operating Officer | Jan 31, 2026 | Option exercise | +42,275 | – | – | 154,254 |
| Kevin Tan CFO & Treasurer | Jan 31, 2026 | Option exercise | +33,075 | – | – | 135,821 |
| Jessie Hanrahan Chief Regulatory Officer | Jan 31, 2026 | Option exercise | +27,625 | – | – | 109,210 |
| Gabriel Brooks Chief Medical Officer | Jan 31, 2026 | Option exercise | +28,225 | – | – | 125,043 |
| Alexander Cumbo President and CEO, Director | Jan 31, 2026 | Option exercise | +100,400 | – | – | 351,189 |
| Paul Herzich Chief Technology Officer | Jan 31, 2026 | Option exercise | +24,675 | – | – | 106,222 |
| David T. Howton Chief Operating Officer | Jan 29, 2026 | Option exercise | +79,341 | – | – | 112,249 |
| Kevin Tan CFO & Treasurer | Jan 29, 2026 | Option exercise | +56,646 | – | – | 102,746 |
| Jessie Hanrahan Chief Regulatory Officer | Jan 29, 2026 | Option exercise | +54,925 | – | – | 81,585 |
| Gabriel Brooks Chief Medical Officer | Jan 29, 2026 | Option exercise | +58,847 | – | – | 96,818 |
| Alexander Cumbo President and CEO, Director | Jan 29, 2026 | Option exercise | +169,401 | – | – | 250,789 |
| Paul Herzich Chief Technology Officer | Jan 29, 2026 | Option exercise | +54,925 | – | – | 81,547 |
| Ilan Ganot Director | Jan 28, 2026 | Sale(10b5-1 plan) | −191 | $6.59 | $1.26K | 17,476 |
| Ilan Ganot Director | Jan 27, 2026 | Option exercise | +389 | – | – | 17,667 |
| Ilan Ganot Director | Jan 27, 2026 | Option exercise | +3,884 | – | – | 99,297 |
| Kevin Tan CFO & Treasurer | Jan 13, 2026 | Sale(10b5-1 plan) | −5,704 | $5.27 | $30.06K | 46,100 |
| Kevin Tan CFO & Treasurer | Jan 9, 2026 | Option exercise | +11,250 | – | – | 51,804 |
| Ian F. Smith Director | Jan 6, 2026 | Option exercise | +4,573 | – | – | 131,264 |
| Ilan Ganot Director | Jan 5, 2026 | Sale | −1,053 | $5.43 | $5.72K | 17,278 |
| Ilan Ganot Director | Jan 3, 2026 | Option exercise | +2,994 | – | – | 18,331 |
| David T. Howton Chief Operating Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −4,932 | $5.11 | $25.20K | 32,908 |
| Paul Herzich Chief Technology Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −2,701 | $5.11 | $13.80K | 26,622 |
| Alexander Cumbo President and CEO, Director | Dec 3, 2025 | Sale(10b5-1 plan) | −10,808 | $5.11 | $55.23K | 81,388 |
| Jessie Hanrahan Chief Regulatory Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −4,483 | $5.11 | $22.91K | 26,660 |
| David T. Howton Chief Operating Officer | Dec 2, 2025 | Option exercise | +13,051 | – | – | 37,840 |
| Paul Herzich Chief Technology Officer | Dec 2, 2025 | Option exercise | +7,239 | – | – | 29,323 |
| Alexander Cumbo President and CEO, Director | Dec 2, 2025 | Option exercise | +28,612 | – | – | 92,196 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Solid Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,166 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jessie Hanrahan Officer | Feb 18, 2026 | 4,134 | $24.07K | Feb 18, 2026 | Settlement of vested restricted stock units |
| Alexander Cumbo Officer, Director | Feb 18, 2026 | 16,644 | $96.92K | Feb 18, 2026 | Settlement of vested restricted stock units |
| David T. Howton Officer | Feb 18, 2026 | 7,469 | $43.49K | Feb 18, 2026 | Settlement of vested restricted stock units |
| Gabriel Brooks Officer | Feb 18, 2026 | 5,563 | $32.40K | Feb 18, 2026 | Settlement of vested restricted stock units |
| Kevin Tan Officer | Feb 18, 2026 | 5,404 | $31.47K | Feb 18, 2026 | Settlement of vested restricted stock units |
| Ilan Ganot Director | Feb 18, 2026 | 2,658 | $15.75K | Feb 18, 2026 | Settlement of vested restricted stock units indirectly held by the reporting person through his wife, Ms. Ganot |
| Paul Herzich Officer | Feb 18, 2026 | 3,616 | $21.06K | Feb 18, 2026 | Settlement of vested restricted stock units |
| Gabriel Brooks Officer | Feb 4, 2026 | 12,616 | $81.27K | Feb 4, 2026 | Settlement of vested restricted stock units |
| Jessie Hanrahan Officer | Feb 4, 2026 | 12,348 | $79.54K | Feb 4, 2026 | Settlement of vested restricted stock units |
| David T. Howton Officer | Feb 4, 2026 | 18,894 | $121.71K | Feb 4, 2026 | Settlement of vested restricted stock units |
| Alexander Cumbo Officer, Director | Feb 4, 2026 | 48,913 | $315.08K | Feb 4, 2026 | Settlement of vested restricted stock units |
| Ilan Ganot Director | Feb 4, 2026 | 7,205 | $46.41K | Feb 4, 2026 | Settlement of vested restricted stock units indirectly held by the reporting person by his wife, Ms. Ganot |
| Paul Herzich Officer | Feb 4, 2026 | 10,905 | $70.25K | Feb 4, 2026 | Settlement of vested restricted stock units |
| Kevin Tan Officer | Feb 4, 2026 | 14,783 | $95.23K | Feb 4, 2026 | Settlement of vested restricted stock units |
| Jessie Hanrahan Officer | Feb 2, 2026 | 26,535 | $170.80K | Feb 2, 2026 | Settlement of performance shares |
See a number that looks wrong?